Postoperative radiotherapy of internal mammary nodes in breast cancer

doi:10.3760/cma.j.issn.1673-422X.2014.11.009

Abstract

Abstract: Internal mammary nodes are part of the first stop of mammary gland lymphatic drainage. It plays an important role in the process of occurrence and development of breast cancer. Whether irradiation internal mammary nodes or not is still a larger controversy. At present, for the early stage patients, the efficacy of internal mammary lymph node irradiation is not clear. For the patients with positive axillary lymph nodes, inboard or central quadrant lesions, postoperative radiotherapy of internal mammary nodes has a certain value.

Key words: Breast neoplasms, Radiotherapy, Internal mammary nodes

吕Qing-Fang , ZHANG Qiu-Ning, WANG Xiao-Hu. Postoperative radiotherapy of internal mammary nodes in breast cancer[J]. Journal of International Oncology, 2014, 41(11): 827-829.

References

［1］ Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast conserving surgery on 10year recurrence and 15year breast cancer death: metaanalysis of individual patient data for 10,801 women in 17 randomised trials［J］. Lancet, 2011, 378（9804）:17071716. ［2］ Sedlmayer F, SautterBihl ML, Budach W, et al. DEGRO practical guidelines: radiotherapy of breast cancer Ⅰ: radiotherapy following breast conserving therapy for invasive breast cancer［J］. Strahlenther Onkol, 2013, 189(10):825833. ［3］ Carkaci S, Adrada BE, Rohren E, et al. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?［J］. Acad Radiol, 2012, 19(5):535541. ［4］ Koo MY, Lee SK, Bae SY, et al. Longterm outcome of internal mammary lymph node detected by lymphoscintigraphy in early breast cancer［J］. J Breast Cancer, 2012, 15(1):98104. ［5］ Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15year survival: an overview of the randomized trials［J］. Lancet, 2005, 366(9503):20872106. ［6］ Hooning MJ, Botma A, Aleman BM, et al. Longterm risk of cardiovascular disease in 10year survivors of breast cancer［J］. J Natl Cancer Inst, 2007, 99(5):365375. ［7］ Matzinger O, Heimsoth I, Poortmans P, et al. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage Ⅰ to Ⅲ breast cancer (EORTC trial 22922/10925)［J］. Acta Oncol, 2010, 49(1):2434. ［8］ NCCN National Comprehensive Cancer Network. 2014 NCCN Breast Cancer Guidelines(2014.V1). America: NCCN.2014. ［9］殷蔚伯，余子豪，徐果镇，等．肿瘤放射治疗学［M］．第四版. 北京：中国协和医科大学出版社， 2008：11641190. ［10］ Stemmer SM, Rizel S, Hardan I, et al. The role of irradiation of the internal mammary lymph nodes in highrisk stage Ⅱ to ⅢA breast cancer patients after highdose chemotherapy: a prospective sequential nonrandomized study［J］. J Clin Oncol, 2003, 21(14):27132718. ［11］ Olson RA, Woods R, Speers C, et al. Does the intent to irradiate the internal mammary nodes impact survival in women with breast cancer? A populationbased analysis in British Columbia［J］. Int J Radiat Oncol Biol Phys, 2012, 83(1):e3541. ［12］ Chang JS, Park W, Kim YB, et al. Longterm survival outcomes following internal mammary node irradiation in stage ⅡⅢ breast cancer: results of a large retrospective study with 12year followup［J］. Int J Radiat Oncol Biol Phys, 2013, 86(5):867872. ［13］ Courdi A, Chamorey E, Ferrero JM, et al. Influence of internal mammary node irradiation on longterm outcome and contralateral breast cancer incidence in nodenegative breast cancer patients［J］. Radiother Oncol, 2013, 108(2):259265. ［14］ Hennequin C, Bossard N, ServagiVernat S, et al. Tenyear survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy［J］. Int J Radiat Oncol Biol Phys, 2013, 86(5):860866. ［15］ Poortmans PSH, Kirkove C, Budach V, et al. Irradiation of the internal mammary and medial supraclavicular lymph nodes in stage Ⅰ to Ⅲ breast cancer: 10 year results of the EORTC radiation oncology and breast cancer groups phase Ⅲ trial 22922/10925［C］. EJC, 2013, 49Suppl 3：abstr BA2. ［16］ Whelan TJ, Olivotto I, Ackerman I, et al. NCICCTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer［C］. Proc Am Soc Clin Oncol, 2011, 29Suppl: abstr LBA1003. ［17］ Nilsson G, Holmberg L, Garmo H. Radiation to supraclavicular and internal mammary lymph nodes in breast cancer increases the risk of stroke［J］. Br J Cancer, 2009, 100(5):811816. ［18］ Darby SC, McGale P, Taylor CW, et al. Longterm mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries［J］. Lancet Oncol, 2005, 6（8）:557565. ［19］ MacDonald SM, Jimenez R, Paetzold P, et al. Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery［J］. Radiat Oncol, 2013, 8:71. ［20］ Qiu PF, Zhao RR, Liu YB, et al. Internal mammary sentinel lymph node biopsy should still be performed, especially in the patient with clinically positive axillary lymph nodes［J］. Breast, 2013, 22(5):9991000. ［21］ Dogan MH, Zincircioglu SB, Aydinol M. Research on different techniques in breast cancer radiotherapy［J］. Contemp Onco (Pozn), 2013, 17(3):291297. ［22］ Oh JL, Buchholz TA. Internal mammary node radiation: a proposed technique to spare cardiac toxicity［J］. J Clin Oncol, 2009, 27(31): e172173.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[6]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[7]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[8]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[9]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[10]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[11]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[12]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[13]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[14]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[15]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.